Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Silo Pharma (Nasdaq: SILO) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) as of June 17, 2026. The stock will continue trading on the Nasdaq Capital Market, and the compliance matter is considered closed.
The company also highlighted confidence in advancing its lead PTSD candidate SPC-15 toward first-in-human trials and progressing its QwikAgents AI agents platform.
Positive
- Regained compliance with Nasdaq minimum bid price rule 5550(a)(2)
- Common stock continues trading on the Nasdaq Capital Market
- Compliance matter with Nasdaq is formally closed
Negative
- None.
News Market Reaction – SILO
In the Jun 18 session, SILO gained 5.34%, reflecting a notable positive market reaction. Argus tracked a trough of -15.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Provisional TBI patent | Positive | -0.2% | Filed provisional patent for ibogaine-based therapeutic targeting traumatic brain injury. |
| Apr 29 | PTSD program update | Positive | +1.3% | Highlighted PTSD program amid expanded federal support for psychedelic therapies. |
| Apr 22 | AI platform acquisition | Positive | -16.9% | Acquired Qwikagents AI platform, adding AI agent business alongside drug pipeline. |
| Apr 20 | PTSD policy tailwind | Positive | +29.3% | Positioned SPC-15 PTSD candidate to benefit from new U.S. psychedelic research order. |
| Apr 06 | European patent allowance | Positive | +49.0% | Received EPO intent to grant patent on prophylactic 5-HT4 agonist PTSD therapy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The stock often reacts sharply to IP and regulatory catalysts, with mostly positive alignment but occasional negative divergence on strategic expansion news.
Key Terms
minimum closing bid price requirement regulatory
first-in-human clinical trial medical
ptsd medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo’s common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.
“We appreciate the loyalty and continuing support from our investors for our business strategies aimed at creating long-term value for stockholders. Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 targeting PTSD and successfully advancing our AI agents platform QwikAgents,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
investors@silopharma.com
